Near-Term Product Pipeline

  Indication Platform Concept Pre-Clinical Phase I/IIA Phase IIB/III
Orthopedic Market Adjunctive treatment for long bone fractures Bone Healing Accelerant        
Adjunctive treatment for total joint replacement Bone Healing Accelerant        
Enhancer & Extender for DBM (demineralized bone) spine Bone Healing Accelerant        
Surgical Site Infection Market Reduction in surgical site infection for colorectal surgery Tissue Healing Accelerant        
Reduction in surgical site infection for sternotomy Tissue Healing Accelerant        
Reducton in surgical site infection for C-Section/hysterectomy Tissue Healing Accelerant        

Allogenic pooled plasma utilized in Carmell’s processing is screened and processed by an FDA registered and AABB accredited U.S. blood bank and is therefore considered free of known blood-borne pathogens. It is then re-screened using sensitive nucleic acid amplification technology (NAT), and additional steps are taken to remove any new viral contaminants that conventional screening may miss. The final product is also terminally sterilized after packaging, meeting FDA’s and EMA’s stringent requirements to ensure safety.